secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001193125-22-077792
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022
--------------------------------------------------------------------------

- FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.
- Cash and equivalents $149M as of Dec 31, 2021, expected to fund operations into 2024.
- Q4 2021 net loss $16M vs net income $7.8M in Q4 2020; full year net loss $110.7M.
- Phase 2 PRECISION 1 trial (TSC1/TSC2 alterations) open; initial data expected H1 2023.
- Operating expenses Q4 $16.9M, up from $5.7M; G&A increased due to commercial buildout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/0001193125-22-077792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/d326646d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-077792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer